Lupkynis(voclosporin)
Lupkynis (voclosporin) is a protein pharmaceutical. Voclosporin was first approved as Lupkynis on 2021-01-22. It is used to treat lupus nephritis in the USA. It has been approved in Europe to treat lupus nephritis. The pharmaceutical is active against peptidyl-prolyl cis-trans isomerase A.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Lupkynis
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Voclosporin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LUPKYNIS | Aurinia Pharmaceuticals | N-213716 RX | 2021-01-22 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lupkynis | New Drug Application | 2024-05-09 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| lupus nephritis | EFO_0005761 | D008181 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
VOCLOSPORIN, LUPKYNIS, AURINIA | |||
| 2026-01-22 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
27 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lupus nephritis | D008181 | EFO_0005761 | — | — | 2 | 5 | — | 1 | 8 |
| Nephritis | D009393 | — | N05 | — | 2 | 5 | — | 1 | 8 |
| Uveitis | D014605 | HP_0000554 | H20.9 | — | — | 4 | — | — | 4 |
| Keratoconjunctivitis sicca | D007638 | EFO_1000906 | — | 1 | 2 | 1 | — | — | 3 |
| Dry eye syndromes | D015352 | — | H04.12 | 1 | 2 | 1 | — | — | 3 |
| Kidney transplantation | D016030 | — | — | — | 1 | 1 | — | 1 | 3 |
| Psoriasis | D011565 | EFO_0000676 | L40 | — | — | 3 | — | — | 3 |
| Panuveitis | D015864 | EFO_1001082 | H44.11 | — | — | 3 | — | — | 3 |
| Keratoconjunctivitis | D007637 | — | H16.2 | 1 | 1 | 1 | — | — | 2 |
| Intermediate uveitis | D015867 | EFO_1000986 | — | — | — | 2 | — | — | 2 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Eye diseases | D005128 | EFO_0003966 | H44 | — | 1 | — | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | — | — | — | 1 |
| Covid-19 | D000086382 | — | — | — | 1 | — | — | — | 1 |
| Focal segmental glomerulosclerosis | D005923 | EFO_0004236 | — | — | 1 | — | — | — | 1 |
| Systemic lupus erythematosus | D008180 | HP_0002725 | M32 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Immunosuppression therapy | D007165 | — | — | — | — | — | — | 1 | 1 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Voclosporin |
| INN | voclosporin |
| Description | Voclosporin is a homodetic cyclic peptide. |
| Classification | Protein |
| Drug class | cyclosporin derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C=C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C |
Identifiers
| PDB | — |
| CAS-ID | 515814-01-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2218919 |
| ChEBI ID | — |
| PubChem CID | 6918486 |
| DrugBank | DB11693 |
| UNII ID | 2PN063X6B1 (ChemIDplus, GSRS) |
Target
Agency Approved
PPIA
PPIA
Organism
Homo sapiens
Gene name
PPIA
Gene synonyms
CYPA
NCBI Gene ID
Protein name
peptidyl-prolyl cis-trans isomerase A
Protein synonyms
Cyclophilin A, Cyclosporin A-binding protein, epididymis secretory sperm binding protein Li 69p, peptidylprolyl isomerase A (cyclophilin A), PPIase A, Rotamase A, T cell cyclophilin
Uniprot ID
Mouse ortholog
Ppia (268373)
peptidyl-prolyl cis-trans isomerase A (Q9R137)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 480 documents
View more details
Safety
Black-box Warning
Black-box warning for: Lupkynis
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,777 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use